top of page

Do you have ulcerative coltis?

If you have moderate to severe ulcerative colitis (UC) and you live in the Los Angeles area,  you may be eligible to participate in a new clinical trial looking at the safety, tolerability, pharmacokinetics and efficacy of a potential new oral medication called AT-177.  The trial is 8 weeks long with a 4 week follow up.  It is being conducted at UCLA.  All patients will be randomly assigned to one of three doses of the active drug AT-177.  Patients must be between 18 and 80 years of age and meet specific inclusion and exclusion criteria in order to participate.  There is no cost to participate.

​

Details of the clinical trial can be found here.

Please enter your details and we will connect you if you meet the eligibility criteria.

Are you able to commute to UCLA every 2 weeks (and possibly more) during the study?
Have you been diagnosed by a doctor as having ulcerative coltis?
Has it been at least 3 months since your diagnosis?
Thanks for submitting your details.  If you are eligible for the study, a member of the clinical team will contact you.

Disclaimer - Choosing to participate in a study is an important personal decision. Talk with your doctor, family members or friends when considering to join a study.  AT177 has not been demonstrated to be safe or effective for any indication and is not available for sale in the United States or any other country. 

​

Your personal information is being requested to allow an initial assessment to be made about your potential eligibility for participation in a clinical trial.  By submitting the requested information, you are consenting for your personal and health information to be viewed by representatives from Azora Therapeutics and its affiliates, and disclosed to a relevant trial site for further assessment.  Your data will be stored on our servers until completion of the study.  It will not be used for any purposes other than the purpose stated above. Potential participants should contact us if they wish to have their information updated or removed from theses systems prior to the completion of the study.

Azora Logo PNG.png

AT177 and AT193 aare for investigational use only and have not been approved by the FDA or any other regulatory agency for commercial use.  The safety and efficacy of these products have not been established for use.

Copyright © 2023 by Azora Therapeutics Inc and Azora Therapeutics Australia Pty Ltd.  All Rights Reserved.

bottom of page